Christina is the Chief Operating Officer of the Company. Ms. Yi has over 25 years of leadership roles in the production and delivery of transformative medicines. As Chief Operating Officer, she oversees all operations of the production and distribution of the Company’s products, including supply chain, program management, human resources and information technology. Prior to joining the Company, Ms. Yi was the Chief Operations Officer at Dendreon Pharmaceuticals, LLC, with the responsibility of leading over 400 employees and managing all operational aspects for the production, disposition and delivery of the first FDA-approved immunotherapy treatment for advanced prostate cancer. Before Dendreon, Ms. Yi worked on commercializing multiple novel therapeutics in a Quality role with Amgen and drug development with Xenogen Corporation and Targeted Genetics Corporation. Ms. Yi earned a B.S. in Cell and Molecular Biology from the University of Washington, Seattle, WA.